SEC Company Response from NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) (CIK 0000810509) — Jan 7, 2020
NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) (CIK 0000810509)
Date: Jan. 7, 2020 · CIK: 0000810509 · Accession: 0001437749-20-000263
AI Filing Summary & Sentiment
File numbers found in text: 333-235762
Letter
VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Navidea Biopharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-235762) (the “Registration Statement”)
Re:
Dear Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), the Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on Thursday, January 9, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
If you have any questions regarding this request, please contact our outside counsel, Faith Charles of Thompson Hine LLP, at (212) 908-3905 or the undersigned at (614) 793-7500. Please also call Faith Charles as soon as the Company’s Registration Statement on Form S-3 has been declared effective. Thank you for your attention to this matter.
Sincerely,
NAVIDEA BIOPHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm navb20200107_corresp.htm January 7, 2020 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Navidea Biopharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-235762) (the “Registration Statement”) Dear Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), the Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on Thursday, January 9, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable. If you have any questions regarding this request, please contact our outside counsel, Faith Charles of Thompson Hine LLP, at (212) 908-3905 or the undersigned at (614) 793-7500. Please also call Faith Charles as soon as the Company’s Registration Statement on Form S-3 has been declared effective. Thank you for your attention to this matter. Sincerely, NAVIDEA BIOPHARMACEUTICALS, INC. By: /s/ Jed A. Latkin Name: Jed A. Latkin Title: Chief Executive Officer, Chief Operating Officer & Chief Financial Officer cc: Faith Charles, Thompson Hine LLP